| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.14.2.224 |
| P8608 | Fatcat ID | release_ljpo6dwumjdcjfbqt64i3iw3ne |
| P953 | full work available at URL | https://europepmc.org/articles/PMC352437 |
| https://europepmc.org/articles/PMC352437?pdf=render | ||
| https://journals.asm.org/doi/pdf/10.1128/AAC.14.2.224 | ||
| P932 | PMC publication ID | 352437 |
| P698 | PubMed publication ID | 308792 |
| P50 | author | John A. Washington | Q112429856 |
| P2093 | author name string | J. W. Paisley | |
| P2860 | cites work | Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate | Q24564458 |
| Haemophilus aphrophilusCholecystitis | Q45147603 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| Gram-negative bacteria | Q632006 | ||
| P304 | page(s) | 224-227 | |
| P577 | publication date | 1978-08-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Combined Activity of Clavulanic Acid and Ticarcillin Against Ticarcillin-Resistant, Gram-Negative Bacilli | |
| P478 | volume | 14 |
| Q54542090 | A combination of amoxicillin and clavulanic acid in the treatment of respiratory tract infections caused by amoxicillin-resistant haemophilus influenzae. |
| Q43484203 | Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects |
| Q35672724 | Amoxicillin-clavulanic acid in treatment of urinary tract infection due to gram-negative bacteria resistant to penicillin |
| Q70220884 | Antibiotic resistance |
| Q38006505 | Antimicrobial therapy for the elderly patient |
| Q54524531 | Augmentin (amoxycillin and clavulanic acid) in the treatment of urinary tract infections. |
| Q40283560 | Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo |
| Q34042624 | Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa |
| Q24617277 | Beta-lactamase inhibitors from laboratory to clinic |
| Q28289154 | Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy |
| Q39654236 | Clinical pharmacology of antibiotics and other drugs in cystic fibrosis |
| Q35570220 | Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. |
| Q54549829 | Combinations of clavulanic acid and other beta-lactam antibiotics against strains of Pseudomonas aeruginosa, Serratia marcescens and other bacteria. |
| Q40282177 | Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains |
| Q35650267 | Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli |
| Q35574130 | Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa |
| Q37263001 | Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid |
| Q35575219 | Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa |
| Q40620039 | Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics |
| Q24681289 | In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates |
| Q72585874 | In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers |
| Q54312560 | In vitro susceptibilities of feline and canine Escherichia coli and Pseudomonas spp. isolates to ticarcillin and ticarcillin-clavulanic acid. |
| Q44980543 | In vitro-activity of clavulanic acid and amoxicillin combined against amoxicillin-resistant bacteria |
| Q28270377 | In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics |
| Q40178076 | New antibiotics. New hopes and new problems |
| Q46147437 | Pharmacokinetics and bioavailability of ticarcillin and clavulanate in foals after intravenous and intramuscular administration |
| Q42928992 | Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid |
| Q33789502 | Pharmacologic considerations in the treatment of neonatal septicemia and its complications |
| Q37162193 | Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid |
| Q38528405 | Screening and isolation of antibiotic resistance inhibitors from herb materials IV-resistance inhibitors from Anetheum graveolens and Acorus gramineus |
| Q54395901 | Serum levels and pharmacokinetics of ticarcillin and clavulanic acid in dog following parenteral administration of Timentin. |
| Q72046696 | Simultaneous determination of the binary mixtures of cefsulodin and clavulanic acid by using first-derivative spectrophotometry |
| Q35893199 | Spontaneous bacterial peritonitis: Analysis of treatment and outcome |
| Q54486623 | Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid. |
| Q39850737 | Synergistic effects of dicloxacillin or clavulanic acid in combination with penicillin G or cephalothin against Yersinia enterocolitica |
| Q39797849 | The prevention and treatment of bacterial endocarditis |
| Q24646623 | Three decades of beta-lactamase inhibitors |
| Q70113968 | Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis |
| Q40294726 | Ticarcillin: a review of its pharmacological properties and therapeutic efficacy |
| Q33928681 | Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations |
Search more.